Egfr nucleic acids and uses thereof
AssigneeAvidity Biosciences, Inc.
InventorHanhua HUANG
Life of this patent
Estimating the term…
Abstract
Disclosed herein are molecules and pharmaceutical compositions that mediate RNA interference against EGFR. Also described herein include methods for treating a disease or disorder that comprises a molecule or a pharmaceutical composition that mediate RNA interference against EGFR.
Claims33
A polynucleic acid molecule that mediates RNA interference against EGFR, wherein the polynucleic acid molecule hybridizes to a EGFR target sequence selected from SEQ ID NOs:
- 1-376 with less than 4 mismatched bases, wherein the polynucleic acid molecule comprises at least one 2′ modified nucleotide, at least one modified internucleotide linkage, or at least one inverted abasic moiety, and wherein the polynucleic acid molecule is from about 10 to about 50 nucleotides in length.
A polynucleic acid molecule that mediates RNA interference against EGFR, wherein the polynucleic acid molecule comprises at least 80% sequence identity to a sequence selected from SEQ ID NOs:
- 377-1892.
Dependencies are inferred from the claim text.